This episode takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. Mark Lebwohl, MD, discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.
by The Cutaneous Connection
The podcast The Cutaneous Connection is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.